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The NS5A protein of hepatitis C virus (HCV) plays roles in both virus genome replication and the
assembly of infectious virus particles. NS5A comprises three domains, separated by low-
complexity sequences. Whilst the function of domain I appears to be predominantly involved with
genome replication, the roles of domains II and III are less well defined. It has been reported
previously that a deletion spanning the majority of domain II but retaining the C-terminal 35
residues had no effect on virus production; however, deletion of the entire domain II eliminated
genome replication, pointing to a key role for the C terminus of this domain. Recent work has also
highlighted this region as the potential binding site of the host factor cyclophilin A (CypA). To
define this requirement for replication in more detail, and to investigate the involvement of CypA,
we conducted a mutagenic study of the C-terminal 30 residues of domain II within the context of
both the infectious JFH-1 virus and a JFH-1-derived subgenomic replicon. We showed that 12 of
these residues were absolutely required for virus genome replication, whilst mutations of the
remainder either had no phenotype or exhibited a partial reduction in genome replication. There
was an absolute correlation between the datasets for virus and subgenomic replicon, indicating
that this region is involved solely in the process of genome replication. Comparison of our data
with a previously published analysis of the same region in genotype 1b revealed some important
differences between the two genotypes of HCV.
INTRODUCTION
Hepatitis C virus (HCV) currently infects ~2–3% of the
world’s population, of whom around 85% will progress to
chronic infection where the major outcome is liver
cirrhosis and hepatocellular carcinoma (Shepard et al.,
2005). Current treatment is a combination of pegylated
interferon and ribavirin, but recently the first direct-acting
antivirals targeting the NS3 protease were licensed and
numerous other drugs are in late-stage clinical trials (Yang
et al., 2011). Of particular interest are compounds targeted
to the NS5A protein such as BMS-790052, which show
extraordinarily high potency (Gao et al., 2010). However,
toxicity and the development of drug resistance are
associated with all treatments, highlighting the need for
further research.
HCV has a 9.6 kb positive-sense ssRNA genome coding for
a ~3000 aa polyprotein that is cleaved co- and post-
translationally by both host and viral proteases to produce
ten mature viral proteins. The structural proteins – core
protein, E1 and E2 – are involved in the structure and
formation of virus particles, p7 is a viroporin that may or
may not be a virion component but has roles in virus
assembly and release (Griffin 2010), and non-structural
protein 2 (NS2) contains an autoprotease activity that
cleaves it from NS3 but also has a poorly defined role in
virion morphogenesis (Jirasko et al., 2008; Ma et al., 2011).
The remaining non-structural proteins – NS3, NS4A,
NS4B, NS5A and NS5B – are responsible for replication of
the viral genome and remodelling of the host-cell
architecture and physiology in favour of HCV replication
and persistence (reviewed by Moradpour et al., 2007).
Recently, a full-length clone of a genotype 2a isolate,
termed JFH-1, was shown to be able to undergo the
complete virus life cycle in cell culture without the need for
adaptive mutations, allowing stages of virion assembly and
release to be investigated for the first time (Wakita et al.,
2005).
The NS5A protein comprises three domains linked by two
low-complexity sequences (LCSs) (Fig. 1a) that are either
serine or proline rich (termed LCS I and II, respectively).
Domain I is a highly structured, zinc-binding domain
whose three-dimensional structure shows two different
dimeric conformations (Love et al., 2009; Tellinghuisen
et al., 2005). Domains II and III have been shown to be
natively unstructured, but nuclear magnetic resonanceA supplementary figure is available with the online version of this paper.
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(NMR) and circular dichroism have shown that both these
domains have elements of secondary structure throughout
(Feuerstein et al., 2012; Hanoulle et al., 2009b; Liang et al.,
2007). The protein is anchored to membranes by an N-
terminal amphipathic helix and is an essential component
of the viral genome replication complex (reviewed by He
et al., 2006; Macdonald & Harris 2004), interacting with
other non-structural proteins, for example the NS5B
polymerase (Shirota et al., 2002), and cellular factors such
as human vesicle-associated membrane protein-associated
protein A (Evans et al., 2004). NS5A is also a highly
phosphorylated protein, existing predominantly in two
species: a basally phosphorylated (56 kDa) and a hyper-
phosphorylated (58 kDa) form. This phosphorylation is
widely postulated to act as a molecular switch regulating
the different functions of NS5A (Appel et al., 2005).
The NS5A protein has been ascribed a large number of
functions in multiple stages of the virus life cycle. As well as
perturbing multiple host pathways, it plays critical roles in
both virus replication and the assembly of infectious
virions. In this regard, NS5A has been shown to possess in
vitro RNA-binding activity, as the entire protein, or each
individual domain, expressed in Escherichia coli and
purified, have all been shown to bind genome-derived
RNA sequences (Foster et al., 2010; Hwang et al., 2010).
Domain II of NS5A is known to be required for replication
(Appel et al., 2008), as well as interacting with both host
and viral proteins (Evans et al., 2004; Goh et al., 2001;
Shirota et al., 2002). Specifically, in the context of JFH-1, a
deletion of the C-terminal 35 aa resulted in complete
abrogation of replication, whereas, conversely, deleting the
preceding N-terminal residues of domain II had no effect
on virus replication (Appel et al., 2008). A separate study
utilizing a genotype 1b subgenomic replicon (SGR) found
that small deletions (8–15 residues) within the C-terminal
56 aa of domain II completely abrogated replication, and
further analysis by site-directed mutagenesis identified 23
essential residues within this region (Tellinghuisen et al.,
2008b). However, due to the genotype utilized, it was not
possible to investigate the role of these residues in the
context of the fully infectious virus.
Work has begun to shed light on the potential mechanisms
behind this requirement of domain II for replication, most
notably involving the host factor cyclophilin A (CypA).
CypA is a peptidyl-prolyl isomerase (PPIase) identified as a
critical host factor for the successful infection of many
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Fig. 1. Role of NS5A domain II in replication of the genotype 2a JFH-1 SGR. (a) Sequence of domain II of NS5A targeted for
mutagenesis. The organization of the NS5A protein is shown, highlighting the region of domain II that was mutated in this study.
Residue numbering is shown in relation to the NS5A sequence of JFH-1 (upper numbers) and the JFH-1 polyprotein sequence
(lower numbers). Residues in bold are the consensus sequence conserved in the majority of genotypes (see also Fig. 5 and Fig.
S1, available in JGV Online). (b) Huh7 cells were electroporated with mSGR RNA and seeded into either 96-well plates (for the
luciferase assay) or six-well plates (for Western blotting). Cells were harvested at 72 h p.e. The luciferase data shown is the
mean±SEM of more than three experiments and was normalized to luciferase activity at 4 h p.e. Asterisks denote no statistical
difference (P,0.05) from the WT. (c) Cell lysates were analysed by SDS-PAGE (7.5% acrylamide) and Western blotting for
the indicated proteins.
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viruses, including human immunodeficiency virus, influ-
enza and recently HCV (Fischer et al., 2010). Disruption of
its PPIase activity through chemical inhibitors such as
cyclosporin (CsA), active-site mutations or small interfer-
ing RNA (siRNA) knockdown has been shown to be
deleterious to HCV replication. NMR studies also suggest
that CypA binds via its active site to the C-terminal region
of domain II (Yang et al., 2010), and mutations that confer
a loss of CypA dependency cluster within this region
(Coelmont et al., 2010). This all points towards the domain
II of NS5A forming an interaction with CypA that is critical
for replication, and that disruption of this by mutation/
deletion in domain II is inhibitory to HCV replication.
In this study, we aimed to fully characterize the residues
within this region that are required for either genome
replication or the assembly and release of infectious virus.
Furthermore, we aimed to establish whether residues
essential for replication correspond to the putative binding
sites of CypA. To achieve this, we conducted alanine
scanning mutagenesis of the C-terminal 30 aa of domain II
in the context of the JFH-1 isolate and investigated the
phenotype of these mutants within the HCV life cycle.
Lastly, we investigated whether mutations in this region
disrupted the dependence on CypA for replication by
measuring resistance to CypA inhibition.
RESULTS
Site-directed mutagenesis of NS5A aa 309–338
identifies numerous residues essential for
genome replication
To identify whether residues within domain II are dispens-
able for the HCV life cycle, we undertook a comprehensive
alanine scanning mutagenesis of the C-terminal 30 aa in
domain II of NS5A (Fig. 1a). Single residues were mutated to
alanine by site-directed mutagenesis (or in the case of
alanines in the original sequence, were mutated to glycine)
and cloned into a luciferase-based SGR, mSGR-luc-JFH-1
(see Methods), or a JFH-1 infectious clone construct (mJFH-
1) (Hughes et al., 2009a). To investigate the effect of these
substitutions, in vitro transcripts of the panel of mutants, in
both the replicon and virus, were electroporated into Huh7
cells and the phenotype determined by luciferase activity
(mSGR) or genome quantification by real-time quantitative
reverse transcriptase-PCR (qRT-PCR) (mJFH-1).
In vitro transcripts of the mSGR-luc-JFH-1 construct were
electroporated into Huh7 cells and luciferase activity was
measured at 4, 24, 48 and 72 h post-electroporation (p.e.).
Replication levels of mutant and WT constructs are shown
at 72 h p.e. normalized to the 4 h p.e. signal (Fig. 1b). The 4
h p.e. value was representative of both electroporation
efficiency and input translation. As a negative control, the
NS5B polymerase inactive mutation (with mutation of the
conserved GDD motif to GND) was used (SGR-luc-GND)
(Targett-Adams & McLauchlan, 2005).
Twelve mutations (L309A, P310A, W312A, A313G, N318A,
W325A, R326A, Y330A, V335A, A336G, G337A and C338A)
were shown to completely disrupt the ability of mSGR-luc-
JFH-1 to replicate in Huh7 cells, whilst a further eight
mutations (A311G, R314A, P315A, P319A, P320A, D329A,
P332A and T334A) resulted in a significant reduction
(P.0.05) compared with WT replication. Ten mutations
(D316A, Y317A, L321A, V322A, E323A, S324A, R327A,
P328A, Q331A and P333A) showed no statistically significant
difference (P,0.05) from WT mSGR-luc-JFH-1 replication.
To further support the luciferase data, total protein at 72 h
p.e. was analysed by Western blotting for both NS5A and
tubulin. Fig. 1(c) shows that, in the case of 15 of the 18
replicating mutants, both phosphorylated forms of NS5A
could be detected at levels broadly correlating with the
observed level of replication measured by the luciferase
assay. However, for mutants A311G, P315A and D329A,
the NS5A protein could not be detected, even at higher
exposures of the Western blot (data not shown). For P315A
and D329A, the absence of NS5A was expected, due to the
very low levels of replication observed, but A311G
replicated to levels comparable to R314A and T334A, both
of which had detectable levels of NS5A in cell lysates. This
issue is addressed later in Fig. 3.
To examine whether the mSGR-luc-JFH-1 replication
phenotypes were also observed in the context of the
complete virus life cycle, the panel of substitutions was
cloned into the full-length mJFH-1 infectious clone. In
vitro transcripts were electroporated into Huh7 cells as
described in Methods and incubated for a total of 144 h,
with a 1 : 5 passage at 72 h p.e. At 144 h p.e., total RNA was
extracted from the cells and the HCV genomes quantified
using qRT-PCR. A 144 h incubation time was required in
order to allow the degradation of input RNA in non-
replicating mutants. However, despite this, the negative-
control JFH-1 GND mutant still maintained levels of HCV
genomes (or fragments thereof) at significant levels at 144
h p.e. This background level of HCV RNA at 144 h p.e.
suggested that the 59-UTR (the target of the qRT-PCR
primers) is highly resistant to degradation by cellular
RNases, possible due to the highly structured nature of the
59-UTR as well as the stabilizing effect of the microRNA
miR-122 (Shimakami et al., 2012). There was, however, a
sufficient window between the WT and the GND negative
control to identify a genome replication phenotype for the
panel of mutations. The quantification of HCV genomes
carrying domain II mutations at 144 h p.e. is shown in Fig.
2(a). The replication phenotype of the mutant panel in the
context of full-length virus correlated well with the data
observed in the mSGR-luc-JFH-1 system.
Domain II plays no significant role in the assembly
or release of infectious virions
We and others (Tellinghuisen et al., 2008a) have previously
identified residues in LCS II and domain III of NS5A that
have no phenotype in genome replication but play roles in
NS5A domain II is required for HCV RNA replication
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the later stages of the virus life cycle. For example, the P342A
mutation has no effect on genome replication but reduces
infectious virus titres by 1 log (Hughes et al., 2009b). We
considered that this might also be the case for those residues
within domain II identified in Figs 1 and 2 with no apparent
role in genome replication. To investigate this, RNA
transcripts of full-length mJFH-1 virus containing domain
II mutations were electroporated into Huh7 cells, which
were passaged 1 : 5 at 72 h p.e., prior to determination of
released virus titre at 144 h p.e. by focus-forming assay.
As previously, the negative control was the JFH-1 GND
construct.
Analysis of the effect of domain II mutations on the release
of infectious virus (Fig. 2b) showed that there was a broad
correlation with the genome replication data. Specifically,
those mutants with a WT genome replication phenotype
also produced WT levels of infectious virus, and those that
were reduced significantly from WT for genome replication
also showed a significant reduction in infectious virus. We
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Fig. 3. Expression of non-replicating NS5A domain II mutants. Huh7 cells seeded in six-well plates were transfected with
pCMV10-NS3-5B DNA and harvested at 48 h for Western blot analysis. Lysates were separated by SDS-PAGE (7.5%
acrylamide) and probed with anti-NS5 antibodies and a sheep polyclonal anti-NS5A serum, which reacts with a cellular protein
(arrowhead), acting as a loading control.
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Fig. 2. Effect of NS5A domain II mutations on JFH-1 virus replication and assembly/release. (a) Huh7 cells were electroporated
with full-length mJFH-1 RNA, incubated for 72 h before being passaged 1 : 5 and incubated for a further 72 h. At 144 h p.e., the
cells were harvested in TRIzol, total RNA was extracted and qRT-PCR was conducted on 100 ng total cellular RNA using 59-
UTR TaqMan primers. (b) Huh7 cells were electroporated with mJFH-1 RNA and incubated for 72 h before being passaged
1 : 5 and incubated for a further 72 h. At 144 h p.e., the supernatants were harvested and used to determine the titre of release
virus by focus-forming assay. Asterisks denote no statistical difference (P,0.05) from the WT. f.f.u., Focus-forming units.
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concluded that the reduction in virus titre observed for
domain II mutations stemmed from impairment to
replication and not as a result of specific disruption to
the virus assembly/release pathways. These data provide
further support for the conclusion that the C terminus of
domain II plays a pivotal role in HCV genome replication
but has no role in the assembly or release of infectious virus
particles.
Mutations that eliminate RNA replication do not
disrupt polyprotein processing
In the case of non-replicating mutations, it was important
to establish that this elimination of replication resulted
from a loss or disruption of a specific function of NS5A,
rather than disruption of polyprotein translation or
proteolytic processing. To demonstrate this, the 12 non-
replicating mutants, together with the three mutants for
which NS5A expression could not be observed (A311G,
P315A and D329A; Fig. 1b) and R314A as a representative
mutant with an intermediate phenotype, were cloned into
an expression construct in which the NS3–5B coding
sequences of JFH-1 were expressed from a human
cytomegalovirus (CMV) promoter (pCMV-10-NS3-5B)
(Jones et al., 2009), thus allowing replication-independent
expression of the replicase proteins. These expression
constructs were transfected into Huh7 cells and analysed
for protein expression by Western blotting (Fig. 3). All of
the mutants expressed both phosphorylated forms of NS5A
(the basal p56 and hyperphosphoylated p58), confirming
that the lethal replication phenotype of these mutations
was a direct result of a loss of NS5A function and was not
due to global effects on NS5A structure or inhibition of
polyprotein processing. Notably, mutants P315A and
W325A exhibited lower levels of expression in comparison
with the WT. This may suggest that these two mutants
affected the stability of the protein; however, pulse–chase
analysis would be required to confirm this hypothesis.
Intriguingly, A311G, which was undetectable in the context
of a replicating SGR, could be detected at WT levels in this
assay. This suggests that additional factors may influence
the stability of NS5A when incorporated into active RNA
replication complexes.
Mutation of residues within two potential CypA-
binding motifs has a limited effect on the
sensitivity of replication to CypA inhibition
The function of CypA has been shown to be critical for the
successful replication of HCV. CypA-independent muta-
tions have been identified by both CsA treatment and
siRNA knockdown of CypA (Coelmont et al., 2010; Yang
et al., 2010). Both techniques identified key resistant
mutations that cluster in this C-terminal region of domain
II, specifically R314W, D316E, Y317N (aa 318, 320 and 321
in the HCV Con1 isolate, respectively). When these
mutations were inserted into the replicon (either individually
or in combination), there was a consistent (and additive)
increase in the 50% effective concentration (EC50) of drugs
that inhibit CypA.
These resistant residues are located within a motif (RPDY)
that is present twice within this region of domain II (R314–
Y317 and R327–Y330; Fig. 1a). As mutations in residues in
both of these motifs showed a reduction in genome
replication (R314, P315, D329 and Y330), we considered
that this might be explained by a loss of CypA dependence.
To test this, the EC50 of CsA inhibition for mutations of these
residues was determined. Huh7 cells were electroporated
with in vitro transcripts of mutant and WT mSGR-luc-JFH-
1, treated at 4 h p.e. with CsA (0.01–100 mM, 0.5% DMSO
final concentration) and luciferase activity was determined at
48 h p.e. (Fig. 4). In parallel, (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays were con-
ducted to determine the 50% cytotoxic concentration
(CC50) to confirm that any reduction in luciferase activity
was not a result of cytotoxicity. CsA was not toxic at any of
the concentrations used (data not shown). As experimental
controls, the CsA-resistant mutation D316E was used to
demonstrate an increase in EC50, and the NS5A inhibitor
BMS-790052 was used as a negative control where no shift in
EC50 was expected (Fridell et al., 2010).
In the case of three mutants (R314A, P315A in the first
motif and D329A in the second), the impairment of
replication resulting from alanine substitution was too
great to allow an accurate CsA EC50 to be determined;
however, the sensitivity of these mutants to CsA inhibition
was broadly comparable to that of WT (data not shown).
For the remaining four mutations (D316A, Y317A, R327A
and P328A), an accurate EC50 (Fig. 4) could be
determined. Mutations D316A and P328A resulted in an
~50% increase in sensitivity to CsA treatment (decreased
EC50) when compared with the WT. Conversely, the Y317A
and R327A mutations resulted in a modest increase in CsA
EC50, and, although it was not as dramatic as that of the
major resistance mutation D316E, which showed an
expected 8.5-fold increase in EC50, it was still significant.
As expected, BMS-790052 was equally effective against
both WT and D316E (EC50 of 17.4±5.0 and
24.2±2.1 pM, respectively; data not shown). These data
showed that mutations within this region of domain II are
able to modulate the sensitivity of replication to CypA
inhibition by CsA.
DISCUSSION
In this study, we utilized the HCV genotype 2a isolate JFH-1
to investigate the role of the C-terminal 30 residues of NS5A
domain II within the virus life cycle. We identified 12
residues within this region that were necessary for viral
genome replication, and substitutions of these amino acids
to alanine (or to glycine in the case of alanine residues
within NS5A) eliminated genome replication in both full-
length virus and SGRs. A further eight mutations resulted
in a significant inhibition of replication, implying that,
NS5A domain II is required for HCV RNA replication
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although these residues are not essential, they do contribute
to genome replication. There was, however, no residue
within this region that, when mutated, resulted in a
reduction in released virus titre without a corresponding
reduction in virus replication, implying that this region is
exclusively involved in genome replication. These data
reinforce the conclusion that the primary role of domain II
is in genome replication, and that those residues not
required for replication play no role in the release of
infectious virions. However, we cannot rule out the
possibility that residues essential for replication are also
required for virus assembly and/or release, although such a
duality in function is unlikely and is technically challenging
to address experimentally.
Genotype-specific requirements within domain II
for RNA replication
Two previous studies have assessed the requirements for
genome replication of the corresponding region in the
genotype 1b SGR (Shimakami et al., 2004; Tellinghuisen
et al., 2008b), but as the genotype 1b isolates were not able
to undergo infection in cell culture, investigation of the
later stages of the virus life cycle was precluded. The data
generated in the study presented here allowed us to
compare the residues required for genome replication
between the two genotypes.
As shown in Fig. 5, this region exhibited a high level of
sequence conservation across the genotypes. Ten of the 30
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Fig. 4. Effect of domain II mutations on CsA EC50. Huh7 cells were electroporated with mSGR RNA, seeded into 96-well
plates and treated at 4 h p.e. with serial dilutions of CsA. At 48 h p.e., the cells were harvested and the luciferase activity
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residues were absolutely conserved, and a further ten showed
a very high level of sequence conservation (¢90%; Fig. 5).
One prediction would be that those residues that are abso-
lutely conserved would also play critical roles; however, this
was not entirely the case. Although P310, W325, G337 and
C338 are essential for genome replication in genotypes 1b and
2a, the data for other conserved residues is less clear cut. For
example, in this study, mutations of residues W312, A313,
Y330 and V336 were lethal, but in genotype 1b the corres-
ponding mutations have either a null or partial phenotype.
Focusing on the differences between Con1 and JFH-1, 22
residues were conserved between the two genotypes, yet in
only a minority of these residues did the requirements
match (Fig. 5). In fact, only five residues appeared to be
dispensable for both genotypes. Overall within this region,
77% of residues in the JFH-1 isolate were required for
genome replication compared with only 50% in the Con1
isolate, indicating that this region appears to have greater
importance for genome replication in the JFH-1 isolate.
How might these differences be explained? One possibility
might be in the context of protein–protein interactions, as
this region of NS5A has been reported to interact with the
NS5B polymerase (Shimakami et al., 2004) and the cellular
factor CypA (Hanoulle et al., 2009a; Yang et al., 2010).
Furthermore, a recent NMR study predicted that this
region is the least disordered in domain II with no
propensity to form a helical structure; however, residues
within this region underwent chemical shift changes upon
incubation with the Bin1 SH3 domain (Feuerstein et al.,
2012), indicating that they were directly involved in the
interaction. It is therefore possible that these interactions
might be subtly different between the two genotypes.
Several residues essential for replication map to
CypA interaction sites
As mentioned above, this region of NS5A has been shown
to interact with the cellular PPIase CypA. This interaction
and the PPIase activity of CypA have been shown to be of
critical importance for virus replication, independent of
the effects of CypA on the calcineurin pathway (Coelmont
et al., 2010). Residues A311–N318, T334, G337 and C338
have been shown by NMR to undergo chemical shifts upon
incubation with CypA (Hanoulle et al., 2009a; Yang et al.,
2010), suggestive of a direct interaction. In contrast, we
(Foster et al., 2011) and others (Chatterji et al., 2010) have
shown that D316 and Y317 are not required for CypA
binding in vitro. Our data presented here are consistent
with this latter observation, as, although D316A and Y317A
had no apparent phenotype, mutation of the surrounding
residues to alanine (or to glycine in the case of A311 and
A313) was sufficient either to strongly impair or to
completely abolish virus replication. Somewhat paradox-
ically, D316 and Y317 represent the major determinant for
CypA dependence and CsA susceptibility, and a double
mutant (D316E, Y317N) exhibited 20-fold resistance to
CsA and, unlike WT JFH-1, was able to replicate efficiently
in CypA-silenced cells (Yang et al., 2010). Taken together,
these data are thus consistent with the previously proposed
hypothesis that binding of CypA to the motif PAWARP
between residues 310 and 315 is important for HCV
genome replication (Hanoulle et al., 2009a).
Intriguingly, this motif overlaps with a longer sequence
that is present twice within the region of interest,
WxRPDYxPP (where x is any amino acid) and has a high
level of conservation across all major genotype isolates (Fig.
5). When comparing both occurrences of this motif in
JFH-1, the only consistent pattern that emerged was that
W312 and W325, along with the residues C-terminal to
these (A313 and R326), are both absolutely required.
However, in the Con1 isolate, only the W329A mutation
(corresponding to W325A in JFH-1) was lethal, and
mutation of W316A (JFH-1 W312A) had only a partial
defect. Mutations of the RP residues in the N-terminal
motif impaired replication, whereas the same mutations in
the C-terminal motif had no effect, and the opposite was
M P I W A R P D Y N P P L L E S W K D P D Y V P P V V H G C
L P A W A R P D Y N P P L V E S W R R P D Y Q P P T V A G C  
309
Con1
338
L P I W A R P D Y N P P L L E T W K R P D Y E P P V V H G C
*       *    *       *                 *                       *                      *                   *        *    * 
JFH-1
Consensus
313 342
100 % 
Fig. 5. Requirement of residues within the C-terminal region of domain II for genome replication in the JFH-1 and Con1 isolates.
The effect of alanine mutation on RNA replication was screened by a colony-forming assay (Con1) (Tellinghuisen et al., 2008b)
or by luciferase reporter/qRT-PCR (JFH-1; this study). Red, non-replicating; orange, partial and statistically significant
impairment of replication; green, no effect on replication. The lower part of the figure shows the consensus across this region
based on a subset of isolates representing each genotype (Simmonds et al., 2005). A full alignment of these sequences is
shown in Fig. S1. Filled bars indicate the percentage conservation at each residue, whilst asterisks denote residues that are
100% conserved.
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true of the DY residues. It would be interesting to analyse
the phenotype of combinatorial mutations to determine
whether there is any redundancy resulting from the
duplication. A further twist to this story is the observation
that, in Con1 (Tellinghuisen et al., 2008b), the phenotypes
of mutations of the two DY motifs are opposite to the JFH-
1 phenotype. D320 and Y321 (corresponding to JFH-1
D316 and Y317) are required for genome replication,
whereas D333 and Y334 (JFH-1 D329 and Y330) are not
required. These data argue strongly that it is difficult to
extrapolate between datasets derived from genotypes 1b
and 2a, suggesting that there may well be significant
functional differences between the NS5A proteins of these
two genotypes. An additional confounding factor is the
observation that the phenotype of selected mutants in the
genotype 1b replicon is influenced by the combination of
culture-adaptive mutations present within the remainder
of the replicon. For example, P324A (corresponding to
JFH-1 P320A) is lethal in the context of the GIT replicon
(mutations E1202G and T1280I in NS3, and K1846T in
NS4A) but only displays a partial defect in the NS5A
mutant S2201I replicon (Tellinghuisen et al., 2008b).
In conclusion, we have shown that the C-terminal 30
residues of the NS5A domain II have no role in either the
assembly or release of infectious virus in the genotype 2a
isolate JFH-1, and that the function of this region is
restricted to that of the replication of viral genomic RNA.
Although this role in genomic replication is consistent with
data obtained for genotype 1b, our data highlighted
phenotypic variations between genotypes irrespective of
the high sequence conservation and caution against
extrapolation of datasets between genotypes. A key
challenge for the future is to determine the mechanisms
underpinning how single amino acid changes can com-
pletely eliminate the function of a protein that holds no
intrinsic enzymatic function. In particular, it will be
intriguing to determine whether any of these changes
influence the ability of domain II to interact with either
cellular or viral proteins, or indeed viral RNA. Such studies
are currently under way in our laboratory.
METHODS
Cell culture.Huh7 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma) supplemented with 10% FBS, 100 IU
penicillin ml21, 100 mg streptomycin ml21 and 1% non-essential
amino acids in a humidified incubator at 37 uC in 5% CO2. For virus
propagation, the medium was supplemented with 25 mM HEPES.
DNA constructs. DNA constructs of the full-length pJFH-1 virus
(Wakita et al., 2005) or a luciferase reporter SGR (SGR-luc-JFH-1)
(Targett-Adams & McLauchlan 2005) were used throughout.
Previously, unique restriction sites flanking NS5A, BamHI and AfeI,
were introduced into both the full-length virus and SGR-luc-JFH-1
constructs (denoted as mJFH-1 and mSGR-luc-JFH-1, respectively)
and shown to have no effect on virus genome replication or assembly
and release (Hughes et al., 2009a). Mutagenesis of NS5A was
performed directly on mSGR-luc-JFH-1 constructs or a LITMUS28i
(NEB) subclone of a NS5A containing an NsiI–HindIII fragment of
the JFH-1 cDNA by QuikChange site-directed mutagenesis
(Stratagene) and then cloned into either mSGR-luc-JFH-1 or
mJFH-1 via the flanking BamHI/AfeI sites. The pCMV10-NS3-5B
[NS5A(GFP)] vector (Jones et al., 2009) was reverted to WT NS5A by
cloning in the RsrII–SfiI fragment from mJFH-1, and the NS5A
domain II mutants were then inserted into this WT vector by cloning
the NsiI–RsrII fragment containing the mutation from the corres-
ponding mJFH-1 vector. All mutations were verified by sequencing.
Plasmid and primer sequences are available on request.
DNA transfection. Huh7 cells were seeded at a concentration of
26105 cells per well into six-well plates 24 h prior to transfection
with 3 mg pCMV-NS3-5B construct using polyethylenimine. At 48 h
cells, were washed twice in PBS and lysed in Glasgow lysis buffer
[GLB; 1% Triton X-100, 120 mM KCl, 30 mM NaCl, 5 mM MgCl2,
10% glycerol, 10 mM PIPES/NaOH (pH 7.2)].
In vitro transcription. The DNA constructs, mSGR-luc JFH-1 or
mJFH-1, were linearized by XbaI and overhanging ends were
degraded by mungbean nuclease treatment. The DNA was phenol/
chloroform extracted and 1 mg linearized DNA was used as template
in a 20 ml RiboMAX reaction (Promega). The RNA transcripts were
purified by phenol/chloroform extraction and quantified by absorb-
ance at 260 nm. The RNA was also analysed by agarose gel
electrophoresis to confirm integrity and quantification.
Luciferase-based replication assay. Huh7 cells were washed twice
in DEPC-treated PBS before electroporating 46106 cells in DEPC-
treated PBS with 2 mg RNA at 950 mF and 270 V. The cells were
resuspended in complete medium before being seeded into both 96-
well plates (n56) at 36104 cells per well and six-well plates (n52) at
36105 cells per well; both plates were incubated under cell-culture
conditions. After 4, 24, 48 and 72 h p.e., cells were harvested by lysis
with 30 or 200 ml Passive Lysis Buffer (Promega) for the 96- and six-
well plates, respectively. Luciferase activity was determined for the 96-
well samples on a BMG Labtech plate reader by automated addition
of 50 ml LarI reagent (Promega) and total light emission was
monitored over 12 s.
SDS-PAGE and Western blotting. Cells were washed twice with
PBS, lysed by resuspension in GLB containing protease and
phosphatase inhibitors, and incubated on ice for 15 min. Insoluble
material was pelleted by centrifugation at 500 g for 5 min at 4 uC.
Following separation by SDS-PAGE, proteins were transferred to a
PVDF membrane and blocked in 10% skimmed milk in PBS/0.1%
Tween (PBST). The membrane was incubated with primary antibody
in 5% skimmed milk in PBST, washed in PBST and then incubated
with HRP-conjugated secondary antibody and washed as for the
primary antibody.
Virus replication and release assay. Huh7 cells were washed twice
in DEPC-treated PBS before electroporating 26106 cells in DEPC-
PBS with 1 mg RNA at 950 mF and 270 V. The cells were resuspended
in complete medium and seeded at 16106 cells per well into six-well
plates. At 72 h p.e., the cells were split at 1 : 5 before incubating for a
further 72 h. At 144 h p.e., the cells were harvested in 400 ml TRIzol
for qRT-PCR analysis, whilst the supernatants were removed and
clarified at 2800 g for 5 min at room temperature before storing at
280 uC.
Virus titre by focus-forming assay. Virus supernatants were
clarified at 2800 g for 5 min at room temperature before being titrated
on Huh7 cells as follows. In the 96-well format, clarified virus
supernatants were serially diluted fivefold in complete DMEM plus
HEPES before the addition of 100 ml diluted virus to Huh7 cells seeded
24 h previously into 96-well plates at 86103 cells per well (final volume
200 ml). The cells were incubated under normal cell-culture conditions
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for 72 h before washing in PBS and fixing in 4% paraformaldehyde for
20 min. The cells were permeabilized in 0.1% Triton X-100, 10% FBS
in PBS for 7 min followed by staining with anti-NS5A serum
(Macdonald et al., 2003) diluted 1 : 5000, followed by a corresponding
secondary fluorescent antibody. The foci were counted manually to
determine virus titres.
RNA extraction and qRT-PCR. To quantify the number of HCV
genomes, total cell RNA was extracted using TRIzol following
manufacturer’s instructions (Invitrogen). Total extracted cellular
RNA (100 ng) was analysed by qRT-PCR using a one-step qRT-PCR
Taqman-based kit as directed by the manufacturer (Eurogentec). The
primers and probe designed against the 59-UTR have been described
previously (Takeuchi et al., 1999).
CsA treatment, EC50 and CC50. Huh7 cells were electroporated and
seeded as described for the luciferase-based replication assay. At 4 h
p.e., the cells were treated with CsA at concentrations ranging from
0.01 to 100 mM (0.5% DMSO final), incubated under normal
conditions and harvested at 48 h p.e. in 30 ml Passive Lysis Buffer, and
the luciferase activity was determined as described above. The data
were modelled and the EC50 was calculated using Prism (GraphPad).
Cytotoxicity assays were carried out in parallel to determine the CC50
using a MTT-based system (Sigma Aldridge).
Statistics. Data generated from the luciferase assay and the virus
replication/release assays were subjected to Student’s t-test assuming a
one-tailed, unequal variance to determine statistical difference from
the WT.
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